key: cord-0314260-6sdr7nyt authors: Acevedo, M. L.; Alonso-Palomares, L.; Bustamante, A.; Gaggero, A.; Paredes, F.; Cortampeacutes, C.; Valiente-Echeverrampiacutea, F.; Soto-Rifo, R. title: Infectivity and immune escape of the new SARS-CoV-2 variant of interest Lambda date: 2021-07-01 journal: nan DOI: 10.1101/2021.06.28.21259673 sha: e55e6333e59171ae85169e5320861edf96202e66 doc_id: 314260 cord_uid: 6sdr7nyt Background: The newly described SARS-CoV-2 lineage C.37 was recently classified as a variant of interest by the WHO (Lambda variant) based on its high circulation rates in South American countries and the presence of critical mutations in the spike protein. The impact of such mutations in infectivity and immune escape from neutralizing antibodies are entirely unknown. Methods: We performed a pseudotyped virus neutralization assay and determined the impact of the Lambda variant on infectivity and immune escape using plasma samples from healthcare workers (HCW) from two centers in Santiago, Chile who received the two-doses scheme of the inactivated virus vaccine CoronaVac. Results: We observed an increased infectivity mediated by the Lambda spike protein that was even higher than that of the D614G (lineage B) or the Alpha and Gamma variants. Compared to the Wild type (lineage A), neutralization was decreased by 3.05-fold for the Lambda variant while it was 2.33-fold for the Gamma variant and 2.03-fold for the Alpha variant. Conclusions: Our results indicate that mutations present in the spike protein of the Lambda variant of interest confer increased infectivity and immune escape from neutralizing antibodies elicited by CoronaVac. These data reinforce the idea that massive vaccination campaigns in countries with high SARS-CoV-2 circulation must be accompanied by strict genomic surveillance allowing the identification of new isolates carrying spike mutations and immunology studies aimed to determine the impact of these mutations in immune escape and vaccines breakthrough. The emergence of SARS-CoV-2 variants of concern and variants of interest has been a hallmark of the COVID-19 pandemic during 2021 [1] [2] [3] . The newly assigned SARS-CoV-2 lineage C.37 was recently classified as a variant of interest by the WHO on June 14 th and denominated as the Lambda variant 4 . The presence of this new variant has been reported in more than 20 countries as per June 2021 with most of the available sequences coming from South American countries, particularly from Chile, Peru, Ecuador and Argentina 5 . This new variant of interest is characterized by the presence of a convergent deletion in the ORF1a gene (Δ3675-3677) already described in the Beta and Gamma variants of concern and mutations Δ246-252, G75V, T76I, L452Q, F490S, T859N in the spike protein 6 . The impact of these spike mutations on infectivity and escape to neutralizing antibodies are completely unknown. Chile is currently undergoing a massive vaccination program. According to public data from the Chilean Ministry of Health as per June 27 th 2021, 65.6% of the target population (18 years old and older) have received a complete vaccination scheme 7 . The vast majority (78.2%) of the fully vaccinated population have received the two doses scheme of the inactivated virus vaccine CoronaVac, which has been previously reported to elicit neutralizing antibodies but at lower titers when compared to plasma or sera from convalescent individuals 8-11 . Here, we used our previously described pseudotyped virus neutralization assay 12 Health care workers from two sites in Santiago, Chile were invited to participate. Volunteers received the two-doses scheme of CoronaVac, each dose being administered 28 days apart according to the Chilean vaccination program. Plasma samples were collected between May and June 2021. All participants signed an informed consent before any study procedure was undertaken. Data on SARS-CoV-2 lineages and the date the sample was taken from the sequences available from Chile were obtained from the Consorcio Genomas CoV2 site available at https://auspice.cov2.cl/ncov/chile-global. Vaccination data were obtained from public data from Ministry of Science, Technology, Knowledge and Innovation available at https://github.com/MinCiencia/Datos-COVID19 (Product 83). Pseudotyped viruses carrying different SARS-CoV-2 spike proteins were prepared as we previously described 12 . Briefly, HIV-1-based SARS-CoV-2 pseudotypes were produced in HEK293T cells by transfecting the pNL4.3-ΔEnv-Luc together with the corresponding pCDNA-SARS-CoV-2 Spike coding vector in a 1:1 molar ratio. Plasmids coding a codon-optimized spike lacking the last 19 amino acids of the C-terminal end (SΔ19) known to avoid retention at the endoplasmic reticulum 12 were obtained by gene synthesis or customized site-directed mutagenesis (GeneScript) and contained the following mutations: lineage A (reference sequence), lineage B (D614G), lineage B.1.1.7 (Δ69-70, Δ144, N501Y, A570D, D614G, P681H, T716I, S982A, D1118H), lineage P.1 (L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, T1027I) and lineage C.37 (G75V, T76I, Δ246-252, L452Q, F490S, D614G, T859N). Each pseudotype preparation was cleared by centrifugation at 3,000 rpm at room temperature, quantified using the HIV-1 Gag p24 Quantikine ELISA Kit (R&D Systems), aliquoted in 50% fetal bovine serum (Sigma-Aldrich) and stored at -80 ºC until use. Different amounts of pseudotyped viruses (as determined by the levels of the HIV-1 p24 protein) were used to infect HEK-ACE2 cells and 48 hours later, firefly luciferase activity was measured using the Luciferase Assay Reagent (Promega) in a Glomax 96 Microplate luminometer (Promega). Pseudotyped virus neutralization assays were performed essentially as we previously described 12 . Briefly, serial dilutions of the plasma samples (1:4 to 1:8748) were prepared in . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted July 1, 2021. The study protocol was approved by the Ethics Committee of the Faculty of Medicine at Universidad de Chile (Projects Nº 0361-2021 and Nº 096-2020) and Clínica Santa Maria (Project Nº132604-21). All donors signed the informed consent, and their samples were anonymized. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 1, 2021. ; https://doi.org/10.1101/2021.06.28.21259673 doi: medRxiv preprint An analysis of 3695 sequences from Chile deposited at GISAID as per June 24 th 2021 shows a clear dominance of the SARS-CoV-2 variants Gamma and Lambda during the last trimester accounting, together, for the 79% of all sequences (Appendix Figure 1 ). Interestingly, this Table 1 ). Next, we used the pseudotyped viruses mentioned above to performed neutralization assays using 79 plasma samples from healthy healthcare workers from Universidad de Chile and Clínica Santa María at Santiago, Chile (Appendix, (Figure 2A and 2B, Appendix Table 3 ). No correlation between sex, age, body-. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 1, 2021. ; https://doi.org/10.1101/2021.06.28.21259673 doi: medRxiv preprint mass index (BMI) or smoke status and neutralizing antibody titers were observed in our study cohort (Appendix Figure 2 ). Together, our data revealed that the spike protein of the newly recognized variant of interest Lambda, highly circulating in Chile and South American countries, carries mutations conferring increased infectivity and the ability to escape from neutralizing antibodies elicited by CoronaVac. in the Delta and Epsilon variants 6 . The L452R mutation has been shown to confer immune escape to monoclonal antibodies (mAbs) as well as convalescent plasma [13] [14] [15] [16] . Moreover, the L452R mutation has also been shown to increase viral infectivity 16 and our data suggest that the L452Q mutation present in the Lambda variant might confer similar properties to those described for L452R. Interestingly, the 246-252 deletion in the N-terminal domain (NTD) of the Lambda Spike is located in an antigenic supersite 17-20 and therefore, this deletion might also contribute to immune escape. Moreover, the F490S mutation has also been associated with an escape to convalescent sera 13 . Consistent with these antecedents, our results indicate that the spike protein of the Lambda variant confers immune escape to neutralizing antibodies elicited by the CoronaVac vaccine. Whether the Lambda variant also escapes to the cellular response shown to be elicited by CoronaVac 9 is still unknown. We also observed that the spike protein of the Lambda variant presented increased infectivity when compared with the spike protein of the Alpha and Gamma variants, both of them with reported increased infectivity and transmissibility 21,22 . Together, our data show for the first time that mutations present in the spike protein of the Lambda variant confer escape to neutralizing antibodies and increased infectivity. The evidence presented here reinforces the idea that massive vaccination campaigns in countries with high SARS-CoV-2 circulation rates must be accompanied by strict genomic surveillance aimed to rapidly identify new viral isolates carrying spike mutations as . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 1, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 1, 2021. All authors declare no conflicts of interest . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 1, 2021. Table 1 for statistical analyses. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 1, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 1, 2021. Gamma (lineage P.1) and Lambda (lineage C.37) variants as compared with wild type virus. Results are shown as the difference in neutralization titers of matched samples. P values for the comparison of the ID50 are calculated with Wilcoxon signed-rank test. (B) Box plots indicated the median and interquartile range (IQR) of ID50 for each pseudotyped virus. Factor changes are shown as the difference of geometric mean titer in the ID50 as compared with those for the Wild type pseudotyped virus. Statistical analyses were performed using the Wilcoxon matched-pairs signed rank test. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 1, 2021. 1 -J a n -2 0 2 1 8 -J a n -2 0 2 1 1 5 -J a n -2 0 2 1 2 2 -J a n -2 0 2 1 3 1 -J a n - . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 1, 2021. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted July 1, 2021. SARS-CoV-2 variants, spike mutations and immune escape Will SARS-CoV-2 variants of concern affect the promise of vaccines? SARS-CoV-2 Variants and Vaccines COVID-19 Weekly Epidemiological Update Global overview Susceptibility of Circulating SARS-CoV-2 Variants to Neutralization Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection Insights into neutralizing antibody responses in individuals exposed to SARS-CoV-2 in Chile Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant Antigenic minimalism of SARS-CoV-2 is well as studies aimed to analyze the impact of these mutations in immune escape and vaccines breakthrough. Stratification neutralizing antibody titres (NAbTs) against SARS-CoV-2 variants by sex (A), Age (B), BMI (C) and smoke status (D). Neither factor significantly affects neutralizing antibody titers.